Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.47 |
| ▸ | CTSG | P08311 | 2/20 | 0.46 |
| ▸ | CMA1 | P23946 | 2/20 | 0.46 |
| ▸ | MGLL | Q99685 | 3/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 2/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.40 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3838526 | 0.80 | NPC1 (0.45) | MGLLAKR1C3NPC1RAB9AHSD17B10 | |
| SCHEMBL10221049 | 0.74 | SLC6A2 (0.54) | SLC6A2SLC6A4SLC6A3HSD17B10ALDH1A1 | |
| SCHEMBL11510734 | 0.74 | SLC6A2 (0.52) | FFAR1FFAR4MAOBSLC6A2SLC6A4 | |
| SCHEMBL5736692 | 0.73 | CTSG (0.51) | FFAR1FFAR4CTSGCMA1MGLL | |
| SCHEMBL30228382 | 0.73 | SLC6A2 (0.51) | FFAR1FFAR4MAOBSLC6A2SLC6A4 | |
| SCHEMBL28906705 | 0.71 | PARP14 (0.48) | FFAR1FFAR4MAOBSLC6A2SLC6A4 | |
| SCHEMBL4671118 | 0.70 | LTA4H (0.75) | SLC6A2SLC6A4SLC6A3ALDH1A1HTT | |
| SCHEMBL4671113 | 0.70 | SLC6A2 (0.49) | FFAR1FFAR4MGLLMAOBSLC6A2 | |
| SCHEMBL4263923 | 0.69 | MGLL (0.73) | MGLLMAOBFAAHAKR1C3ALDH1A1 | |
| SCHEMBL27863609 | 0.68 | MGLL (0.71) | MGLLMAOBFAAHAKR1C3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2046739-B1 | SUBSTITUTED ANILINE DERIVATIVES | UCB BIOPHARMA SPRL (BE) | 2015-08-26 | — | — | EP | disclosed |
| EP-2046739-B1 | SUBSTITUTED ANILINE DERIVATIVES | UCB BIOPHARMA SPRL (BE) | 2015-08-26 | — | — | EP | disclosed |
| US-8624022-B2 | Substituted aniline derivatives | UCB PHARMA, S.A. (BE) | 2014-01-07 | — | — | US | disclosed |
| US-8624022-B2 | Substituted aniline derivatives | UCB PHARMA, S.A. (BE) | 2014-01-07 | — | — | US | disclosed |
| US-8624022-B2 | Substituted aniline derivatives | UCB PHARMA, S.A. (BE) | 2014-01-07 | — | — | US | disclosed |
| US-20120029188-A1 | Substituted Aniline Derivatives | UCB PHARMA S.A. (BE) | 2012-02-02 | — | — | US | disclosed |
| US-20120029188-A1 | Substituted Aniline Derivatives | UCB PHARMA S.A. (BE) | 2012-02-02 | — | — | US | disclosed |
| US-20120029188-A1 | Substituted Aniline Derivatives | UCB PHARMA S.A. (BE) | 2012-02-02 | — | — | US | disclosed |
| US-8071582-B2 | Substituted aniline derivatives | UCB PHARMA S.A. (BE) | 2011-12-06 | — | — | US | disclosed |
| US-8071582-B2 | Substituted aniline derivatives | UCB PHARMA S.A. (BE) | 2011-12-06 | — | — | US | disclosed |
| US-20110014271-A1 | Substituted Aniline Derivatives | UCB PHARMA S.A. (BE) | 2011-01-20 | — | — | US | disclosed |
| US-7678785-B2 | Substituted aniline derivatives | UCB PHARMA S.A. (BE) | 2010-03-16 | — | — | US | disclosed |
| US-7678785-B2 | Substituted aniline derivatives | UCB PHARMA S.A. (BE) | 2010-03-16 | — | — | US | disclosed |
| US-7678785-B2 | Substituted aniline derivatives | UCB PHARMA S.A. (BE) | 2010-03-16 | — | — | US | disclosed |
| EP-2046739-A1 | SUBSTITUTED ANILINE DERIVATIVES | UCB Pharma S.A. (BE) | 2009-04-15 | — | — | EP | disclosed |
| US-20080045497-A1 | SUBSTITUTED ANILINE DERIVATIVES | UCB PHARMA S.A. (BE) | 2008-02-21 | — | — | US | disclosed |
| US-20080045497-A1 | SUBSTITUTED ANILINE DERIVATIVES | UCB PHARMA S.A. (BE) | 2008-02-21 | — | — | US | disclosed |
| US-20080045497-A1 | SUBSTITUTED ANILINE DERIVATIVES | UCB PHARMA S.A. (BE) | 2008-02-21 | — | — | US | disclosed |
| WO-2008012524-A1 | SUBSTITUTED ANILINE DERIVATIVES | UCB PHARMA S.A. (BE) | 2008-01-31 | — | — | WO | disclosed |
| WO-2008012524-A1 | SUBSTITUTED ANILINE DERIVATIVES | UCB PHARMA S.A. (BE) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029188-A1 | Substituted Aniline Derivatives | NAT1, DPM1, IL4I1 | FFAR1 2748/4885FFAR4 2934/4885CTSG 2097/4885 |
| US-20080045497-A1 | SUBSTITUTED ANILINE DERIVATIVES | DPM1, ERG28, IL4I1 | FFAR1 2627/4885FFAR4 2318/4885CTSG 3760/4885 |
| US-20110014271-A1 | Substituted Aniline Derivatives | NAT1, DPM1, IL4I1 | FFAR1 2748/4885FFAR4 2934/4885CTSG 2097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.